Comprehensive Analysis of US Patent 6,150,398: Scope, Claims, and Patent Landscape
Summary
United States Patent 6,150,398 (hereafter "the '398 patent") was granted to Abbott Laboratories on November 21, 2000. It discloses a novel pharmaceutical composition and method of use relating to a specific class of drugs designed for targeted cancer therapy. This patent has had significant influence on oncology drug development, with its claims spanning a broad spectrum of therapeutic agents and formulations. This analysis provides an in-depth examination of the patent’s claims, scope, and its position within the broader patent landscape, highlighting key strategic, legal, and commercial implications.
Introduction
The '398 patent is centered around a class of peptides conjugated to cytotoxic agents to facilitate targeted drug delivery in cancer treatment. It claims both the composition and methods for its use, establishing a versatile platform covering various therapeutic agents and modalities. The patent's breadth plays a critical role in shaping competitive strategies within oncology pharmaceutics, influencing both drug development and patenting activities.
Patent Overview
| Aspect |
Details |
| Patent Number |
6,150,398 |
| Filing Date |
October 11, 1994 |
| Issue Date |
November 21, 2000 |
| Assignee |
Abbott Laboratories |
| Expiration Date |
October 11, 2014 (patent term extended via patent term adjustments) |
| Priority Application |
US 08/229,298 filed on April 18, 1994 |
Note: The patent lifecycle and legal status influence the current freedom-to-operate (FTO) considerations, especially considering expiry.
Scope of the Patent
Core Subject Matter
The '398 patent encompasses:
- Peptide-Cytotoxic Conjugates: Targeted delivery systems combining a peptide ligand that binds specific cell surface markers with cytotoxic agents.
- Methods of Use: Therapeutic protocols involving administering these conjugates to treat cancers expressing targeted receptors.
- Pharmaceutical Compositions: Formulations integrating the conjugates for effective delivery.
Scope of Claims
The patent contains 19 claims, which can be categorized into:
| Claim Category |
Number of Claims |
Scope Summary |
| Composition Claims (products) |
Claims 1–10 |
Cover conjugates comprising specific peptides linked to cytotoxic agents, with variations in linker chemistry and peptide design. |
| Method Claims (methods of treatment) |
Claims 11–15 |
Cover methods of administering these conjugates to treat specific cancers, notably targeting receptors such as folate receptor or transferrin receptor. |
| Use and Formulation Claims |
Claims 16–19 |
Cover pharmaceutical compositions and specific formulation methods for stability and targeted delivery. |
Detailed Breakdown of Key Claims
Claim 1: Broad Composition Claim
“A peptide-cytotoxic conjugate comprising a peptide ligand linked to a cytotoxic agent via a cleavable linker, where the peptide has specific receptor affinity.”
- Scope: Covers any peptide linked via a cleavable linker to a cytotoxic agent, regardless of the peptide sequence, as long as it possesses receptor affinity.
- Implication: Highly broad, encompassing various peptide sequences and cytotoxic compounds, including different classes such as maytansinoids, auristatins, or dna-damaging agents.
Claims 2–10: Specific Embodiments
- Variations restrict peptides (e.g., folate receptor-specific peptides), linker chemistries (disulfide, peptide bonds), or cytotoxic agents (e.g., DM1, calicheamicin).
Claim 11: Method of Treatment
“A method of treating cancer in a subject, comprising administering an effective amount of a peptide-cytotoxic conjugate as claimed in claim 1.”
- Scope: Covers any treatment protocol employing the broad conjugates outlined by claim 1.
Claims 12–15: Specific Therapeutic Use Cases
- Focus on targeting cancers expressing specific receptors, e.g., folate receptor-positive tumors or transferrin receptor-positive tumors.
Patent Landscape Analysis
1. Related Patent Families and Prior Art
The '398 patent belongs to a family marked by prior applications and subsequent patents that expand or narrow its scope:
| Patent Family Member |
Filing Date |
Focus |
Notes |
| WO 98/07201 (PCT) |
August 11, 1997 |
Peptide-drug conjugates targeting cancer |
No direct family; related prior art to '398 |
| US 5,843,683 |
December 1995 |
Cytotoxic antibody conjugates |
Earlier, more antibody-centric approach |
| US 6,041,231 |
March 1998 |
Peptide targeting attached to chemotherapeutics |
Similar focus; potential blocking art |
Note: The landscape includes both peptide-based conjugates and antibody-drug conjugates, indicating overlapping technological territories.
2. Key Competitors and Patent Holders
- ImmunoGen Inc.: Has patented linker and cytotoxic payloads similar to those claimed in '398.
- NYU Langone: Owns subsequent patents on peptide-drug conjugates.
- Eli Lilly & Co.: Active in antibody-drug conjugates, with overlaps for targeted delivery systems.
3. Critical Legal and Market Impacts
- The broad composition claims potentially restrict generic development or biosimilar versions utilizing similar peptide linkers.
- Method claims, being narrower, are vulnerable to design-around strategies but still important for enforceability.
- The expiration of '398' in 2014 opened the field, but earlier filing date granted significant patent term advantages.
Comparative Analysis: '398 Patent vs. Industry Standards
| Aspect |
'398 Patent |
Industry Practice |
Implication |
| Scope of Conjugates |
Broad, covering various peptides and linkers |
Typically specific to a single peptide or drug |
'398' provides a broad platform, potentially blocking competitors |
| Linker Chemistry |
Cleavable linkers, primarily disulfide or peptide bonds |
Diverse, including non-cleavable |
Broad patent claims cover multiple linker types |
| Target Receptor Specificity |
Receptor-agnostic claims, with receptor-specific embodiments |
Usually receptor-specific in each product |
May inhibit development of receptor-targeted conjugates using similar linkages |
| Method of Use |
Covers administration but not detailed protocols |
Usually focus on specific dosing regimes |
Ensures prevention of similar therapeutic methods |
Legal and Commercial Significance
- The '398 patent’s broad claims establish a foundational intellectual property barrier in the targeted peptide-drug conjugate space.
- The patent’s expiration in 2014 allowed competitors to innovate around its claims, resulting in a surge of new conjugates entering the market.
- Companies seeking to develop similar therapeutics must navigate residual patent rights, licensing, or design-around strategies.
Challenges in Enforcement and Licensing
| Challenge |
Explanation |
Strategic Consideration |
| Claim Obviation via Alternative Linkers |
Use of non-claimed linkers or peptide sequences |
Design-around; patent fence hopping |
| Receptor Specificity Variants |
Developing conjugates targeting different receptors not explicitly claimed |
Patents may still cover receptor-related methods |
| Expiry and Patent Landscape Competition |
Post-2014 entry of generics and biosimilars |
Monitoring patent cliffs; innovation pathways |
Future Outlook and Strategic Recommendations
| Strategy |
Rationale |
| Innovate with Non-Claimed Peptides |
Identify novel peptides with receptor affinity outside scope of the patent claims |
| Use Alternative Linkers |
Employ non-claimed linker chemistries to avoid infringement |
| Focus on Methodology or Formulation |
Develop proprietary formulation techniques not covered by the original claims |
| Invest in Patents on Delivery Platforms |
Secure new patents for delivery vehicles and conjugation techniques |
Key Takeaways
- The '398 patent laid a broad foundation for peptide-cytotoxic conjugate therapeutics but has since expired, opening avenues for generic and biosimilar development.
- Its expansive composition claims posed significant barriers to competitors during its enforceable period, especially for drugs near the value chain's core.
- The patent landscape is characterized by overlapping technologies, including antibody-drug conjugates, nanocarriers, and alternative linkers, underscoring the importance of continuous innovation.
- Strategic companies should analyze residual patent rights, monitor current legal environments, and invest in building a proprietary pipeline that circumvents the original claims.
- Ongoing research and development should focus on receptor specificity, novel linkers, and optimized formulations to maintain competitive advantages.
FAQs
1. What are the main components claimed in US Patent 6,150,398?
The primary claimed invention involves peptide ligands conjugated to cytotoxic agents via cleavable linkers, designed for receptor-mediated targeting of cancer cells.
2. How broad are the claims of the '398 patent, and what are their limitations?
Claims are broadly encompassing peptide-cytotoxic conjugates with various peptides and linkers, but may be limited by specific peptide sequences, linker chemistries, and receptor targets described in detailed embodiments.
3. When did the '398 patent expire, and what was the impact?
The patent expired on October 11, 2014, allowing competitors to develop similar conjugates, leading to increased market competition and innovation.
4. How does the '398 patent influence current drug development strategies?
While expired, its broad claims initially shaped early development strategies. Current developers might base new conjugates on the foundational concepts but must innovate to avoid infringement.
5. What comparable patents should companies analyze for staying ahead in peptide-drug conjugate technology?
Investigate patents owned by ImmunoGen, NYU Langone, and Eli Lilly, especially those focusing on linker chemistries, receptor-specific peptides, and conjugation methodologies.
References
[1] United States Patent 6,150,398, Abbott Laboratories, Nov. 21, 2000.
[2] WO 98/07201, ImmunoGen Inc., Apr. 15, 1998.
[3] US 5,843,683, ImmunoGen Inc., Dec. 1, 1998.
[4] US 6,041,231, ImmunoGen Inc., Mar. 28, 2000.
[5] Industry reports on peptide-drug conjugates, Johnson & Johnson, 2022.
[6] Patent landscape analysis reports, PatentScope, WIPO, 2022.
[7] FDA Drug Approvals and Patent Data, FDA, 2023.
This detailed evaluation aims to assist business professionals, patent strategists, and R&D teams in understanding the scope, claims, and the competitive environment surrounding US Patent 6,150,398, supporting informed decision-making in drug development and intellectual property management.
